BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260323
DTEND;VALUE=DATE:20260326
DTSTAMP:20260515T010906
CREATED:20260210T171107Z
LAST-MODIFIED:20260210T171107Z
UID:42862-1774224000-1774483199@www.pharmajournalist.com
SUMMARY:11th Innate Killer Summit
DESCRIPTION:The 11th Innate Killer Summit stands at the forefront of innovation in innate immunity\, offering an unparalleled platform for exploring the next generation of NK cell-based therapies and innate immune strategies. As the biopharma industry accelerates its focus on immuno-oncology and cell therapy\, this is the only summit that brings together leading experts and decision-makers to address the scientific\, clinical\, and commercial challenges shaping the dynamic NK field. \nThis year’s faculty includes trailblazers from companies driving NK cell innovation\, such as Artiva Biotherapeutics\, Alloplex Biotherapeutics\, Glycostem\, Indapta Therapeutics\, ImmuneBridge\, and Senti Bio\, alongside academic leaders from institutions like the University of Pennsylvania and MD Anderson Cancer Center. Their insights will illuminate breakthroughs in NK cell engineering\, combination strategies\, and scalable manufacturing solutions that are crucial for advancing these therapies from the bench to the bedside. \nAttendees will gain exclusive access to discussions on optimizing NK cell persistence\, enhancing cytotoxicity\, and overcoming tumor microenvironment challenges. The program also delves into clinical trial progress\, regulatory pathways\, and investment trends\, providing a comprehensive view of how NK cell platforms are transforming cancer treatment and unlocking new therapeutic frontiers. \nThe summit provides a unique opportunity to capture the latest scientific developments\, strategic partnerships\, and commercialization strategies that are redefining the immunotherapy landscape. Expect candid conversations with industry leaders\, data-driven insights\, and forward-looking perspectives on how innate immunity is shaping the future of oncology. \nTo know more visit: https://ter.li/5fn4q8
URL:http://www.pharmajournalist.com/event/11th-innate-killer-summit/
LOCATION:The Westin San Diego Bayview\, 400 W Broadway\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260324
DTEND;VALUE=DATE:20260327
DTSTAMP:20260515T010906
CREATED:20260107T092223Z
LAST-MODIFIED:20260107T092251Z
UID:42661-1774310400-1774569599@www.pharmajournalist.com
SUMMARY:Immune Resetting: B-Cell Mediated & Beyond
DESCRIPTION:Immune Resetting: B-Cell Mediated & Beyond Summit is redefining the conversation around immune modulation and therapeutic innovation. As the global biopharma industry accelerates its focus on autoimmune and inflammatory diseases\, this summit provides an exclusive platform for uncovering the next wave of breakthroughs in B-cell biology and beyond. \nThe event brings together leading immunologists\, clinical researchers\, and pharma executives to explore how precision targeting of B-cell pathways is transforming treatment paradigms. From novel mechanisms of immune resetting to advanced biologics and cell-based strategies\, attendees will gain unparalleled insights into the science driving durable responses and improved patient outcomes. \nConnect with experts from Cabaletta Bio\, GentiBio\, Kite Pharma\, FAU\, Cullian Therapeutics\, Kali Therapeutics\, University of Pittsburgh\, Bristol Myers Squibb\, Oblenio Bio\, and more. \nBeyond the science\, the summit addresses critical challenges in translating these innovations into the clinic\, covering biomarker development\, regulatory considerations\, and scalable manufacturing solutions. With autoimmune disorders and chronic inflammation representing multi-billion-dollar markets\, the discussions will highlight how emerging therapies can meet unmet needs and unlock new commercial opportunities. \nExpect deep dives into cutting-edge research\, candid conversations on investment trends\, and strategic perspectives from industry leaders shaping the next generation of immune-modulating therapies. \nJoin the summit to discover how immune resetting is not just a scientific milestone but a transformative force in global healthcare\, positioning biopharma at the forefront of innovation and patient-centric solutions. \nSee what the current attendees are looking forward to: \n“I look forward to hearing and seeing the latest developments in immune resetting and meeting with a diverse group of researchers in this field. I am also excited to present Hinge’s GEM-DIMER molecule\, HB2198\, for depletion of CD19/CD20 expressing B cells.” \nSenior Director – Preclinical Development\, Hinge Bio  \n“I am interested to share our observations for B-cell depletion and reconstitution in Rese-cel treated individuals and hear what others have seen in their trials.” \nPrincipal Scientist\, Cabaletta Bio 
URL:http://www.pharmajournalist.com/event/immune-resetting-b-cell-mediated-beyond/
LOCATION:AKA Back Bay\, Boston\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260324
DTEND;VALUE=DATE:20260327
DTSTAMP:20260515T010906
CREATED:20260123T104451Z
LAST-MODIFIED:20260123T110056Z
UID:42781-1774310400-1774569599@www.pharmajournalist.com
SUMMARY:9th Gene Therapy Development Summit
DESCRIPTION:Gene therapy is entering a defining new chapter. After a period of challenge and recalibration\, the field is regaining momentum\, driven by resilient teams who remain committed to transforming patients’ lives. With renewed confidence\, fresh investment\, and major acquisitions signalling a return to growth\, the industry is refocusing on overcoming the critical barriers of safety\, efficacy\, scalability\, and commercial viability. \nThe 9th Gene Therapy Development Summit returns to Boston as the premier meeting point for the global gene therapy community. Bringing together 70+ senior leaders\, academic and technical experts from organisations including Bayer\, Astellas Pharmaceuticals\, REGENXBIO\, AskBio\, Ocugen\, CureDuchenne Ventures and more\, this industry-led forum provides an unrivalled opportunity to share insights\, restore confidence\, and chart a sustainable path forward for gene therapy development. \nDesigned to span the full end-to-end development pipeline\, the summit connects professionals across pre-clinical development\, manufacturing\, analytical development\, clinical operations\, and regulatory affairs. Across 3 days of cutting-edge strategic and technical sessions\, attendees will gain practical learnings on next-generation delivery technologies\, gene editing\, assay development\, and scalable manufacturing strategies\, all with a focus on optimising clinical impact and improving risk–benefit profiles. \nNetworking sits at the heart of the summit experience. With 10+ dedicated networking breaks\, a CEO & Investor Panel\, and carefully curated opportunities to meet peers\, partners\, and decision-makers\, the event is built to foster meaningful\, long-term industry connections. Whether you are looking to exchange technical insights\, explore collaboration opportunities\, or build strategic partnerships\, this is the place to connect with the people shaping the future of gene therapy. \nFeaturing 70+ world-leading speakers\, including C-level executives\, scientific innovators\, and regulatory leaders\, the summit offers a truly comprehensive and collaborative environment for learning\, discussion\, and deal-making. From early-stage development through to clinical and commercial success\, this is your definitive forum to stay ahead in an evolving gene therapy landscape. \nTo learn more about the event\, visit our website here: https://ter.li/b0hfxq
URL:http://www.pharmajournalist.com/event/9th-gene-therapy-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR